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were treated with H-89, a PKA inhibitor, W-7, a calmodulin inhibitor
or LY294002, a PI3K inhibitor prior to 4a-PDD stimulation in SOX9-
dependent reporter assay. To examine the chondrogenic differentiation,
ATDC5 cells were co-stimulated with 0 to 120 nM 4a-PDD and 10mg/ml
insulin for 10 day, then cells were stained with alcian blue. The amount of
SOX9 protein was estimated by Western Blot analysis using anti-SOX9
antibody.
Results: We have screened 120,000 cDNA clones and identiﬁed
46 genes that activated SOX9-dependent reporter activity. In cDNA mi-
croarray analysis, the mRNA levels of Sox5, Sox6, Iﬁtm5, Myd116, Mef2c
and TRPV4 genes were elevated during chondrogenic differentiation of
ATDC5 cells treated with insulin. TRPV4, a cation channel molecule was
further investigated in this study since it had a strong effect on SOX9-
dependent transcription. mRNA expression of TRPV4 gene was observed
in ATDC5, C3H10T1/2, murine primary chondrocytes prepared from the
rib cages and hind limb buds in embryonic day12 embryos, but not in
NIH3T3. When ATDC5 cells or C3H10T1/2 cells were treated with various
concentration of 4a-PDD, SOX9-dependent transcription was elevated in
dose dependent manner and this effect was abolished by the addition
of ruthenium red, a TRPV antagonist. In ATDC5 cells, H-89 and W-7
inhibited SOX9-dependent reporter activity caused by the stimulation with
4a-PDD while LY294002 did not. When ATDC5 cells were co-stimulated
with 4a-PDD and insulin, GAG accumulation was signiﬁcantly increased
as compared with insulin alone whereas 4a-PDD alone showed no effect.
Similar result was obtained in C3H10T1/2 cells co-stimulated with 4a-
PDD and BMP-2. Co-stimulation with 4a-PDD demonstrated further ele-
vations of mRNAs for type II collagen and aggrecan in ATDC5 cells when
compared to insulin alone. 4a-PDD stimulation increased the amount of
SOX9 protein in both ATDC5 and C3H10T1/2 cells.
Conclusions: We have identiﬁed TRPV4 by its ability to activate SOX9-
dependent transcription. Activation of TRPV4 promoted chondrogenic
differentiation of ATDC5 cells in cooperation with insulin and C3H10T1/2
cells in corporation with BMP-2 in vitro. The protein level of SOX9 was
increased by the stimulation with 4a-PDD. These observations suggest
that TRPV4 may correlate the process of chondrogenesis.
143 BENEFICIAL EFFECTS OF LIVER X RECEPTOR
(LXR) MODULATION ON MATRIX METABOLISM AND
PROSTAGLANDIN E2 (PGE2) PRODUCTION IN CARTILAGE
Z. Yang1, N. Li1, M.A. Rivera-Bermudez1, S.S. Glasson1, L.A. Collins-
Racie1, E.R. LaVallie1, S. Nagpal2, E.A. Morris1, C.R. Flannery1.
1Women’s Health & Musculoskeletal Biology, Wyeth Research,
Cambridge, MA, USA, 2Women’s Health & Musculoskeletal Biology,
Wyeth Research, Collegeville, PA, USA
Purpose: Osteoarthritis (OA), the most common arthritic condition in
humans, is characterized by the progressive degeneration of articular car-
tilage accompanied by chronic joint pain. Inﬂammatory mediators, such as
cytokines and prostaglandin E2 (PGE2) which are elevated in OA joints,
play important roles in the progression of cartilage degradation and pain-
associated nociceptor sensitivity. LXRs possess potent anti-inﬂammatory
properties, possibly through antagonism of the NFúB signaling pathway.
This study was undertaken to evaluate the function of LXRs in cartilage,
particularly their capability to inhibit degradation of matrix proteins such
as aggrecan, and production of inﬂammatory and pain mediators such
as PGE2.
Methods: Mouse cartilage explant culture: Hip cartilage from wild type
and Lxrb−/− mice were collected and cultured in serum-free medium
with or without Il-1b to study the role of Lxrb in regulating cartilage
matrix metabolism and inﬂammation. Culture medium pooled from wt or
Lxrb−/− explant cultures was analyzed for aggrecanase-generated AGEG
aggrecan neoepitope.
Human cartilage explant study : Cartilage explants from human OA joints
were treated with/without Il-1b/Oncostatin M +/− cotreatment with LXR
agonist GW3965 (10 days) to measure the effect of LXR activation on
cartilage matrix degradation and the PGE2 production. Culture medium
was analyzed for aggrecanase-generated AGEG aggrecan neoepitope.
TLDA (Taqman Low Density Array) analysis: A TLDA was designed
to include a list of selected genes known to be important in cartilage
metabolism and inﬂammation. Cartilage RNA from 5 human cartilage
samples treated with/without Il-1b/Oncostatin M +/− GW3965 was ana-
lyzed to determine the effects of GW3965 treatment on the expression of
genes such as ADAMTS4, mPGES, TIMP3, MMP-1 and MMP-13.
Results:We have found that both LXRa and b are expressed in cartilage,
with LXRb being the predominant isoform. We show that genetic disrup-
tion of Lxrb gene expression in mice results in signiﬁcantly increased
proteoglycan (aggrecan) degradation and PGE2 production in articular
cartilage treated with Il-1b, indicating a protective role of LXRs in car-
tilage. Using human cartilage explants, we have found that activation
of LXRs by a synthetic agonist signiﬁcantly reduces cytokine-induced
degradation and loss of aggrecan from the tissue. Furthermore, LXR
activation dramatically diminished basal level as well as cytokine-induced
PGE2 production by human osteoarthritic cartilage. These effects were
achieved at least partly by repression of the expression of ADAMTS4,
a physiological cartilage aggrecanase, and microsomal prostaglandin E
synthase-1, a key enzyme in the PGE2 synthesis pathway.
Conclusions: Modulation of LXR signaling in cartilage using small
molecule agonists may have great potential for OA therapy, not only to
treat symptoms such as pain by blocking PGE2 synthesis, but also to
prevent and possibly reverse disease progression by blocking cartilage
matrix degradation.
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Purpose: S100A8 and S100A9 calcium binding proteins are implicated
in inﬂammatory arthritis. Recently S100A8 and S100A9 were shown
to be localized in murine and human growth plate and articular car-
tilage chondrocytes and their expression upregulated by inﬂammatory
cytokines. To-date however, the changes in S100A8, S100A9 and their
complex (S100A8/S100A9) in cartilage during the onset and progression
of osteoarthritis (OA), and their effect on chondrocyte metabolism have
not been examined. This prompted us to determine (1) the in vivo ex-
pression and immunolocalization of S100A8, S100A9 in cartilage during
progressive cartilage destruction in an OA model in mice; (2) the effect
of interleukin-1a (Il-1) and retinoic acid (RetA) on S100A8 and S100A9
expression and the immunolocalization of S100A8 and S100A9 in mouse
cartilage explants in vitro; and (3) the effect of S100A8 and S100A9 on
the expression by chondrocytes of key extracellular matrix molecules and
matrix degrading enzymes.
Methods: S100A8 and S100A9 in vitro protein localization and gene
expression were determined in chondrocytes in a surgically induced mice
model of OA and in mouse femoral head cartilage explants stimulated
with Il-1 or RetA. The effect of recombinant S100A8, S100A9 or the
complex on the expression of aggrecan, collagen type II, ADAMTS-1,
-4 & -5, MMP-1, -3, -13 & -14 and TIMPs-1, -2 & -3 by primary adult
ovine articular chondrocytes was determined using quantitative reverse
transcriptase real time polymerase chain reaction (qRT-PCR).
Results: Positive immunostaining for intracellular S100A8 but not S100A9
was found in normal articular chondrocytes in mice. Loss of the chondro-
cytes S100A8 staining occurred in OA, in contrast to the positive reactivity
for both S100A8 and S100A9 in chondrocytes in inﬂammatory arthritis.
However, there was an increase in chondrocyte S100A8 and S100A9
gene expression in early OA which decreased below baseline in late
disease. In vitro, stimulation with Il-1 but not RetA, increased chondrocyte
S100A8 and S100A9 mRNA and protein levels. Homodimeric S100A8
and S100A9, but not the heterodimeric complex, signiﬁcantly upregulated
chondrocyte ADAMTS-1, -4 and -5, MMP-1, -3 and -13 gene expression,
while collagen type II and aggrecan mRNAs were signiﬁcantly decreased.
Conclusions: Our data suggests that intracellular S100A8, but not
S100A9, has a physiological role in normal articular chondrocytes in mice.
However, the release of homodimeric S100A8 or S100A9 into the pericel-
lular microenvironment, where they may act as cytokine-like molecules
upregulating MMPs and aggrecanases while decreasing aggrecan and
collagen mRNA expression, may contribute to cartilage degradation in
OA. As extracellular S100A8/S100A9 complex does not regulate chon-
drocyte genes, an imbalance in regulation of the individual S100A8 or
S100A9 proteins maybe important in this disease. New efforts to prevent
the progression of OA might include strategies that target increased
chondrocytes S1008 and S100A9 mRNA, release of the proteins from
the cell and or the signaling/receptors of the homodimers, all of which
might be an important goal in managing OA.
